Shenzhen Zhongge Biotechnology Co. Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agent coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4) targeting moiety via linkers acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorders, transplant rejection, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.
Sevenless Therapeutics Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, pain, dementia, Noonan syndrome, Parkinson's disease and neurofibromatosis type 1.
Gachon University has divulged quinoxaline compounds acting as proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) and its mutant inhibitors reported to be useful for the treatment of cancer.
Synnovation Therapeutics Inc. has prepared and tested phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer and more.
Ongoing policy issues in the U.S., including the Inflation Reduction Act and recent proposals under President Donald Trump’s administration, have wide ranging implications for the global biopharmaceutical industry, speakers at Bio Korea 2025 said May 8, including a heightened need for all biotechs to draft regulatory strategies.
Histone acetyltransferase p300 (EP300) inhibitors have been reported in a Kronos Bio Inc. patent and are described as potentially useful for the treatment of cancer and inflammatory disorders.
Hitgen Ltd. has prepared and tested interleukin-17 receptor A (IL17RA; CD217) antagonists reported to be useful for the treatment of autoimmune disease, cancer, infections, asthma, multiple sclerosis, psoriasis, rheumatoid arthritis and inflammatory disorders.
Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
RSS
